JP2010528987A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010528987A5 JP2010528987A5 JP2010507576A JP2010507576A JP2010528987A5 JP 2010528987 A5 JP2010528987 A5 JP 2010528987A5 JP 2010507576 A JP2010507576 A JP 2010507576A JP 2010507576 A JP2010507576 A JP 2010507576A JP 2010528987 A5 JP2010528987 A5 JP 2010528987A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- group
- pharmaceutical composition
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 106
- 239000008194 pharmaceutical composition Substances 0.000 claims 30
- 125000000217 alkyl group Chemical group 0.000 claims 17
- 229910052739 hydrogen Inorganic materials 0.000 claims 17
- 239000001257 hydrogen Substances 0.000 claims 17
- 238000000034 method Methods 0.000 claims 17
- 229910052736 halogen Inorganic materials 0.000 claims 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims 7
- 150000002367 halogens Chemical group 0.000 claims 7
- 239000000651 prodrug Substances 0.000 claims 7
- 229940002612 prodrug Drugs 0.000 claims 7
- 125000003107 substituted aryl group Chemical group 0.000 claims 7
- 241000711549 Hepacivirus C Species 0.000 claims 5
- 108010047761 Interferon-alpha Proteins 0.000 claims 5
- 102000006992 Interferon-alpha Human genes 0.000 claims 5
- 230000008878 coupling Effects 0.000 claims 5
- 238000010168 coupling process Methods 0.000 claims 5
- 238000005859 coupling reaction Methods 0.000 claims 5
- 150000002148 esters Chemical class 0.000 claims 5
- 230000037406 food intake Effects 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- -1 2 -cyclopropyl Chemical group 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims 4
- 238000003786 synthesis reaction Methods 0.000 claims 4
- 230000002194 synthesizing effect Effects 0.000 claims 4
- 102100037850 Interferon gamma Human genes 0.000 claims 3
- 108010074328 Interferon-gamma Proteins 0.000 claims 3
- 108091005804 Peptidases Proteins 0.000 claims 3
- 239000004365 Protease Substances 0.000 claims 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 3
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical class C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 235000013305 food Nutrition 0.000 claims 3
- 235000012631 food intake Nutrition 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 108010010648 interferon alfacon-1 Proteins 0.000 claims 3
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000002777 nucleoside Substances 0.000 claims 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 2
- BENKAPCDIOILGV-RQJHMYQMSA-N (2s,4r)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1C[C@H](O)C[C@H]1C(O)=O BENKAPCDIOILGV-RQJHMYQMSA-N 0.000 claims 1
- UJQBOUAGWGVOTI-XSSZXYGBSA-N 1-[(2r,4s,5r)-4-azido-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@](O)(N=[N+]=[N-])C1 UJQBOUAGWGVOTI-XSSZXYGBSA-N 0.000 claims 1
- IWUCXVSUMQZMFG-RGDLXGNYSA-N 1-[(2s,3s,4r,5s)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide Chemical compound N1=C(C(=O)N)N=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 IWUCXVSUMQZMFG-RGDLXGNYSA-N 0.000 claims 1
- TZYVRXZQAWPIAB-FCLHUMLKSA-N 5-amino-3-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4h-[1,3]thiazolo[4,5-d]pyrimidine-2,7-dione Chemical compound O=C1SC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O TZYVRXZQAWPIAB-FCLHUMLKSA-N 0.000 claims 1
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 claims 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 1
- 229940121740 Inosine monophosphate dehydrogenase inhibitor Drugs 0.000 claims 1
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 claims 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical group N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 claims 1
- GLWHPRRGGYLLRV-XLPZGREQSA-N [[(2s,3s,5r)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](N=[N+]=[N-])C1 GLWHPRRGGYLLRV-XLPZGREQSA-N 0.000 claims 1
- 229960004748 abacavir Drugs 0.000 claims 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 claims 1
- 229960001997 adefovir Drugs 0.000 claims 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 229960000724 cidofovir Drugs 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 229940014461 combivir Drugs 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000002348 inosinate dehydrogenase inhibitor Substances 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 229950003954 isatoribine Drugs 0.000 claims 1
- 230000003908 liver function Effects 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 229940127073 nucleoside analogue Drugs 0.000 claims 1
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
- 150000003222 pyridines Chemical class 0.000 claims 1
- 229960000329 ribavirin Drugs 0.000 claims 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical group N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims 1
- 229960000311 ritonavir Drugs 0.000 claims 1
- 239000003730 rna directed rna polymerase inhibitor Substances 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
- NHKZSTHOYNWEEZ-AFCXAGJDSA-N taribavirin Chemical compound N1=C(C(=N)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NHKZSTHOYNWEEZ-AFCXAGJDSA-N 0.000 claims 1
- 229950006081 taribavirin Drugs 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 229930192474 thiophene Natural products 0.000 claims 1
- 230000009265 virologic response Effects 0.000 claims 1
- FPULJIHNWKBSCZ-UHFFFAOYSA-N CC(N(C1)Cc2c1cccc2)=O Chemical compound CC(N(C1)Cc2c1cccc2)=O FPULJIHNWKBSCZ-UHFFFAOYSA-N 0.000 description 1
- FTXOZGZEHSVRFY-IKOVWHKNSA-N CCOC(C(CNC([C@H](C[C@H](C1)O)N1C1=O)=O)=C=CCCCCC[C@@H]1NC(C(F)(F)F)=O)=O Chemical compound CCOC(C(CNC([C@H](C[C@H](C1)O)N1C1=O)=O)=C=CCCCCC[C@@H]1NC(C(F)(F)F)=O)=O FTXOZGZEHSVRFY-IKOVWHKNSA-N 0.000 description 1
- 0 CC[C@@]1C(CC(C2)C2(C(N*)=O)NC(C(CC(C2)O*)N2C(C(CC**)N*)=O)=O)C(*)C1* Chemical compound CC[C@@]1C(CC(C2)C2(C(N*)=O)NC(C(CC(C2)O*)N2C(C(CC**)N*)=O)=O)C(*)C1* 0.000 description 1
- JVKMNJPBSOZEKG-UHFFFAOYSA-N OC(C1(CCC2)N2C(CNC(C(F)(F)F)=O)=O)C1=O Chemical compound OC(C1(CCC2)N2C(CNC(C(F)(F)F)=O)=O)C1=O JVKMNJPBSOZEKG-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91589607P | 2007-05-03 | 2007-05-03 | |
| US95763007P | 2007-08-23 | 2007-08-23 | |
| US1564407P | 2007-12-20 | 2007-12-20 | |
| PCT/US2008/062552 WO2008137779A2 (en) | 2007-05-03 | 2008-05-02 | Novel macrocyclic inhibitors of hepatitis c virus replication |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010528987A JP2010528987A (ja) | 2010-08-26 |
| JP2010528987A5 true JP2010528987A5 (en:Method) | 2011-06-16 |
Family
ID=39638815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010507576A Pending JP2010528987A (ja) | 2007-05-03 | 2008-05-02 | Ｃ型肝炎ウイルス複製の新規大環状阻害剤 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20090155209A1 (en:Method) |
| EP (2) | EP2177523A1 (en:Method) |
| JP (1) | JP2010528987A (en:Method) |
| KR (1) | KR20100024920A (en:Method) |
| CN (1) | CN101784549A (en:Method) |
| AP (1) | AP2009005053A0 (en:Method) |
| AR (1) | AR066448A1 (en:Method) |
| AU (1) | AU2008247509A1 (en:Method) |
| BR (1) | BRPI0811020A2 (en:Method) |
| CA (1) | CA2686138A1 (en:Method) |
| CL (1) | CL2008001274A1 (en:Method) |
| CO (1) | CO6251243A2 (en:Method) |
| EA (1) | EA200971026A1 (en:Method) |
| EC (1) | ECSP099780A (en:Method) |
| IL (1) | IL201757A0 (en:Method) |
| MA (1) | MA31496B1 (en:Method) |
| MX (1) | MX2009011867A (en:Method) |
| NZ (1) | NZ581606A (en:Method) |
| SG (1) | SG174809A1 (en:Method) |
| TN (1) | TN2009000457A1 (en:Method) |
| TW (1) | TW200906830A (en:Method) |
| WO (1) | WO2008137779A2 (en:Method) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003007697A (ja) * | 2001-06-21 | 2003-01-10 | Hitachi Kokusai Electric Inc | 半導体装置の製造方法、基板処理方法および基板処理装置 |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| EA019888B1 (ru) * | 2005-07-25 | 2014-07-30 | Интермьюн, Инк. | Промежуточное соединение для получения макроциклических ингибиторов репликации вируса гепатита с и способ его синтеза |
| KR20080056295A (ko) * | 2005-10-11 | 2008-06-20 | 인터뮨, 인크. | Ｃ형 간염 바이러스 복제를 억제하기 위한 화합물 및 방법 |
| KR20090024834A (ko) * | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | Ｃ형 간염 바이러스 복제의 신규 억제제 |
| BRPI0811447A2 (pt) | 2007-05-10 | 2014-10-29 | Intermune Inc | Compostos, composição farmacêutica e métodos de inibição da atividade da protease ns3/ns4, de tratamento da fibrose hepática e de intensificação da função hepática num indivíduo tendo infecção de vírus da hepatite c. |
| KR20110005869A (ko) * | 2008-04-15 | 2011-01-19 | 인터뮨, 인크. | Ｃ형 간염 바이러스 복제의 신규한 마크로사이클릭 억제제 |
| US20090285774A1 (en) * | 2008-05-15 | 2009-11-19 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20090285773A1 (en) * | 2008-05-15 | 2009-11-19 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| AR075584A1 (es) * | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
| EP2417134B1 (en) | 2009-04-08 | 2017-05-17 | Idenix Pharmaceuticals LLC. | Macrocyclic serine protease inhibitors |
| US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
| CA2769652A1 (en) | 2009-08-05 | 2011-02-10 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv |
| WO2011025849A1 (en) * | 2009-08-27 | 2011-03-03 | Merck Sharp & Dohme Corp. | Processes for preparing protease inhibitors of hepatitis c virus |
| US20110081315A1 (en) | 2009-09-28 | 2011-04-07 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| JP2013505951A (ja) * | 2009-09-28 | 2013-02-21 | エフ．ホフマン−ラ ロシュ エルティーディー | Ｃ型肝炎ウイルス複製の新規の大環状インヒビター |
| AU2011344075A1 (en) * | 2010-12-14 | 2013-05-09 | Merck Sharp & Dohme Corp. | Process and intermediates for preparing macrolactams |
| SG191759A1 (en) | 2010-12-30 | 2013-08-30 | Enanta Pharm Inc | Phenanthridine macrocyclic hepatitis c serine protease inhibitors |
| US8937041B2 (en) | 2010-12-30 | 2015-01-20 | Abbvie, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
| WO2012109398A1 (en) | 2011-02-10 | 2012-08-16 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2744507A4 (en) | 2011-08-19 | 2015-01-28 | Merck Sharp & Dohme | CRYSTAL FORMS OF AN HCV PROTEASE HEMMER |
| CN104436197A (zh) | 2011-10-21 | 2015-03-25 | 艾伯维公司 | 至少两种直接作用抗病毒剂的组合产品 |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| AR088463A1 (es) | 2011-10-21 | 2014-06-11 | Abbvie Inc | Metodos para el tratamiento de hcv |
| CN104136038A (zh) * | 2012-02-29 | 2014-11-05 | 东丽株式会社 | 体腔积液抑制剂 |
| UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
| JP6154474B2 (ja) | 2012-10-19 | 2017-06-28 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃ型肝炎ウイルス阻害剤 |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2914598B1 (en) | 2012-11-02 | 2017-10-18 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2914614B1 (en) | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| JP6342922B2 (ja) | 2013-03-07 | 2018-06-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃ型肝炎ウイルス阻害剤 |
| WO2014145095A1 (en) | 2013-03-15 | 2014-09-18 | Gilead Sciences, Inc. | Macrocyclic and bicyclic inhibitors of hepatitis c virus |
| EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
| US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| CA3112326A1 (en) | 2018-09-12 | 2020-03-19 | Novartis Ag | Antiviral pyridopyrazinedione compounds |
| CN120842223A (zh) | 2019-09-26 | 2025-10-28 | 诺华股份有限公司 | 抗病毒吡唑并吡啶酮化合物 |
| US12083099B2 (en) | 2020-10-28 | 2024-09-10 | Accencio LLC | Methods of treating symptoms of coronavirus infection with viral protease inhibitors |
Family Cites Families (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3547119A (en) | 1967-12-08 | 1970-12-15 | Baxter Laboratories Inc | Catheter assembly |
| US4211771A (en) | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
| US4311137A (en) | 1980-04-30 | 1982-01-19 | Sherwood Medical Industries Inc. | Infusion device |
| US4531937A (en) | 1983-01-24 | 1985-07-30 | Pacesetter Systems, Inc. | Introducer catheter apparatus and method of use |
| US4755173A (en) | 1986-02-25 | 1988-07-05 | Pacesetter Infusion, Ltd. | Soft cannula subcutaneous injection set |
| GB8815265D0 (en) * | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
| US5539122A (en) | 1989-05-23 | 1996-07-23 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5354866A (en) | 1989-05-23 | 1994-10-11 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5310562A (en) | 1989-11-22 | 1994-05-10 | Margolin Solomon B | Composition and method for reparation and prevention of fibrotic lesions |
| US5716632A (en) | 1989-11-22 | 1998-02-10 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
| US5518729A (en) | 1989-11-22 | 1996-05-21 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
| EP0674513B1 (en) | 1992-12-29 | 1996-09-25 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5545143A (en) | 1993-01-21 | 1996-08-13 | T. S. I. Medical | Device for subcutaneous medication delivery |
| US6342610B2 (en) | 1993-05-20 | 2002-01-29 | Texas Biotechnology Corp. | N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US5624949A (en) * | 1993-12-07 | 1997-04-29 | Eli Lilly And Company | Protein kinase C inhibitors |
| US6693072B2 (en) * | 1994-06-02 | 2004-02-17 | Aventis Pharmaceuticals Inc. | Elastase inhibitors |
| US5756466A (en) * | 1994-06-17 | 1998-05-26 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| US6090822A (en) | 1995-03-03 | 2000-07-18 | Margolin; Solomon B. | Treatment of cytokine growth factor caused disorders |
| UA58494C2 (uk) | 1995-06-07 | 2003-08-15 | Зенека Лімітед | Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну |
| US6232333B1 (en) | 1996-11-21 | 2001-05-15 | Abbott Laboratories | Pharmaceutical composition |
| TWI222441B (en) | 1997-11-26 | 2004-10-21 | Dimensional Pharm Inc | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors |
| US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| US6277830B1 (en) | 1998-10-16 | 2001-08-21 | Schering Corporation | 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon |
| US6608027B1 (en) * | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
| US7256005B2 (en) | 1999-08-10 | 2007-08-14 | The Chancellor, Masters And Scholars Of The University Of Oxford | Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity |
| AU2001253124A1 (en) * | 2000-04-05 | 2001-10-23 | Schering Corporation | Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties |
| IL151935A0 (en) * | 2000-04-19 | 2003-04-10 | Schering Corp | Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising alkyl and aryl alanine p2 moieties |
| US7244721B2 (en) * | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| MY143322A (en) * | 2000-07-21 | 2011-04-15 | Schering Corp | Peptides as ns3-serine protease inhibitors of hepatitis c virus |
| AU2002305450A1 (en) * | 2001-05-08 | 2002-11-18 | Yale University | Proteomimetic compounds and methods |
| MXPA04000293A (es) * | 2001-07-11 | 2004-05-04 | Vertex Pharma | Inhibidores de serina proteasa biciclica de puente. |
| US6867185B2 (en) * | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| RU2004133044A (ru) * | 2002-04-11 | 2006-01-27 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Ингибиторы сериновых протеаз, в частности, протеазы ns3-ns4a hcv |
| MXPA04010527A (es) * | 2002-04-26 | 2004-12-13 | Gilead Sciences Inc | Acumulacion celular de analogos de fosfonato de los compuestos inhibidores de la proteasa del virus de inmunodeficiencia humana (vih). |
| AU2003301959A1 (en) * | 2002-05-20 | 2004-06-03 | Bristol-Myers Squibb Company | Substituted cycloalkyl p1' hepatitis c virus inhibitors |
| EP1506000B9 (en) * | 2002-05-20 | 2011-08-31 | Bristol-Myers Squibb Company | Heterocyclicsulfonamide hepatitis c virus inhibitors |
| MY140680A (en) * | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| ES2361011T3 (es) * | 2002-05-20 | 2011-06-13 | Bristol-Myers Squibb Company | Inhibidores del virus de la hepatitis c. |
| US20040138109A1 (en) * | 2002-09-30 | 2004-07-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | Potent inhibitor of HCV serine protease |
| PL199412B1 (pl) * | 2002-10-15 | 2008-09-30 | Boehringer Ingelheim Int | Nowe kompleksy rutenu jako (pre)katalizatory reakcji metatezy, pochodne 2-alkoksy-5-nitrostyrenu jako związki pośrednie i sposób ich wytwarzania |
| NZ543250A (en) * | 2003-04-02 | 2008-12-24 | Boehringer Ingelheim Int | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
| EP1615947A2 (en) * | 2003-04-10 | 2006-01-18 | Boehringer Ingelheim International GmbH | Process for preparing macrocyclic compounds |
| EP1613620A1 (en) * | 2003-04-11 | 2006-01-11 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| EP1629000B1 (en) | 2003-04-16 | 2009-02-18 | Bristol-Myers Squibb Company | Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus |
| US7125845B2 (en) * | 2003-07-03 | 2006-10-24 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis C serine protease inhibitors |
| UY28500A1 (es) * | 2003-09-05 | 2005-04-29 | Vertex Pharma | Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc. |
| JP4685775B2 (ja) * | 2003-09-18 | 2011-05-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | セリンプロテアーゼ、とりわけｈｃｖｎｓ３−ｎｓ４ａプロテアーゼの阻害剤 |
| TW200528472A (en) * | 2003-10-10 | 2005-09-01 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV ns3-ns4a protease |
| RS20060259A (sr) * | 2003-10-14 | 2008-08-07 | Intermune Inc., | Makrociklične karboksilne kiseline i acilsulfonamidi kao inhibitori replikacije hcv |
| US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| AU2004285019B9 (en) * | 2003-10-27 | 2011-11-24 | Vertex Pharmaceuticals Incorporated | HCV NS3-NS4A protease resistance mutants |
| US7309708B2 (en) * | 2003-11-20 | 2007-12-18 | Birstol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2005053735A1 (en) * | 2003-11-20 | 2005-06-16 | Boehringer Ingelheim International Gmbh | Method of removing transition metals, especially from metathesis reaction products |
| KR20060118532A (ko) * | 2003-12-11 | 2006-11-23 | 쉐링 코포레이션 | Ｃ형 간염 바이러스 ｎｓ３／ｎｓ４ａ 세린 프로테아제의억제제 |
| BRPI0508186A (pt) * | 2004-02-27 | 2007-08-14 | Schering Corp | compostos como inibidores de ns3 serina protease de vìrus da hepatite c |
| KR20060124725A (ko) * | 2004-02-27 | 2006-12-05 | 쉐링 코포레이션 | Ｃ형 간염 바이러스 ｎｓ3 프로테아제의 억제제 |
| EP1730142B1 (en) * | 2004-02-27 | 2011-06-29 | Schering Corporation | Novel ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus |
| AR048413A1 (es) * | 2004-02-27 | 2006-04-26 | Schering Corp | Compuestos prolina 3,4- (ciclopentil) - fusionados , como inhibidores de serina proteasa ns3 del virus de la hepatitis c |
| EP1749007A2 (en) * | 2004-03-30 | 2007-02-07 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| US7939538B2 (en) * | 2004-06-28 | 2011-05-10 | Amgen Inc. | Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases |
| DE102004033312A1 (de) * | 2004-07-08 | 2006-01-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Kontinuierliches Metatheseverfahren mit Ruthenium-Katalysatoren |
| WO2006007708A1 (en) * | 2004-07-20 | 2006-01-26 | Boehringer Engelheim International Gmbh | Hepatitis c inhibitor peptide analogs |
| CA2577812A1 (en) * | 2004-08-27 | 2006-03-09 | Schering Corporation | Acylsulfonamide compounds as inhibitors of hepatitis c virus ns3 serine protease |
| EP1794179A1 (en) * | 2004-09-17 | 2007-06-13 | Boehringer Ingelheim International Gmbh | Ring-closing metathesis process in supercritical fluid |
| DE102005002336A1 (de) * | 2005-01-17 | 2006-07-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Durchführung von kontinuierlichen Olefin-Ringschluss-Metathesen in komprimiertem Kohlendioxid |
| AU2006242475B2 (en) * | 2005-05-02 | 2011-07-07 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| US7608592B2 (en) * | 2005-06-30 | 2009-10-27 | Virobay, Inc. | HCV inhibitors |
| US7601686B2 (en) * | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TWI389908B (zh) * | 2005-07-14 | 2013-03-21 | Gilead Sciences Inc | 抗病毒化合物類 |
| US7470664B2 (en) * | 2005-07-20 | 2008-12-30 | Merck & Co., Inc. | HCV NS3 protease inhibitors |
| EA019888B1 (ru) * | 2005-07-25 | 2014-07-30 | Интермьюн, Инк. | Промежуточное соединение для получения макроциклических ингибиторов репликации вируса гепатита с и способ его синтеза |
| AR055361A1 (es) * | 2005-07-29 | 2007-08-22 | Medivir Ab | Inhibidores macrociclicos del virus de la hepatitis c |
| KR20080056295A (ko) * | 2005-10-11 | 2008-06-20 | 인터뮨, 인크. | Ｃ형 간염 바이러스 복제를 억제하기 위한 화합물 및 방법 |
| US7772183B2 (en) * | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7741281B2 (en) * | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7601752B2 (en) * | 2005-11-16 | 2009-10-13 | Hoffmann-La Roche Inc. | Pyrrolidine derivatives |
| US7728148B2 (en) * | 2006-06-06 | 2010-06-01 | Enanta Pharmaceuticals, Inc. | Acyclic oximyl hepatitis C protease inhibitors |
| KR20090024834A (ko) * | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | Ｃ형 간염 바이러스 복제의 신규 억제제 |
| EP2049474B1 (en) * | 2006-07-11 | 2015-11-04 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| ES2448494T3 (es) * | 2006-07-13 | 2014-03-14 | Achillion Pharmaceuticals, Inc. | Péptidos de 4-amino-4-oxobutanoilo en calidad de inhibidores de la replicación viral |
| US20090035267A1 (en) * | 2007-07-31 | 2009-02-05 | Moore Joel D | Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors |
| US7635683B2 (en) * | 2006-08-04 | 2009-12-22 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl tripeptide hepatitis C virus inhibitors |
| US7718612B2 (en) * | 2007-08-02 | 2010-05-18 | Enanta Pharmaceuticals, Inc. | Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors |
| CN101674844A (zh) * | 2006-08-04 | 2010-03-17 | 英安塔制药有限公司 | 四唑基大环类c型肝炎丝氨酸蛋白酶抑制剂 |
| US7605126B2 (en) * | 2006-08-11 | 2009-10-20 | Enanta Pharmaceuticals, Inc. | Acylaminoheteroaryl hepatitis C virus protease inhibitors |
| US20090098085A1 (en) * | 2006-08-11 | 2009-04-16 | Ying Sun | Tetrazolyl acyclic hepatitis c serine protease inhibitors |
| US7662779B2 (en) * | 2006-08-11 | 2010-02-16 | Enanta Pharmaceuticals, Inc. | Triazolyl macrocyclic hepatitis C serine protease inhibitors |
| US20090035268A1 (en) * | 2007-08-01 | 2009-02-05 | Ying Sun | Tetrazolyl acyclic hepatitis c serine protease inhibitors |
| US20080038225A1 (en) * | 2006-08-11 | 2008-02-14 | Ying Sun | Triazolyl acyclic hepatitis c serine protease inhibitors |
| US7687459B2 (en) * | 2006-08-11 | 2010-03-30 | Enanta Pharmaceuticals, Inc. | Arylalkoxyl hepatitis C virus protease inhibitors |
| US20080107625A1 (en) * | 2006-11-01 | 2008-05-08 | Bristol-Myers Squibb Company | Inhibitors of Hepatitis C Virus |
| US20080107623A1 (en) * | 2006-11-01 | 2008-05-08 | Bristol-Myers Squibb Company | Inhibitors of Hepatitis C Virus |
| US8343477B2 (en) * | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| US7772180B2 (en) * | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| ES2470568T3 (es) * | 2006-11-17 | 2014-06-24 | Janssen R&D Ireland | Inhibidores macroc�clicos del virus de la hepatitis C |
| WO2008098368A1 (en) * | 2007-02-16 | 2008-08-21 | Boehringer Ingelheim International Gmbh | Inhibitors of hepatitis c ns3 protease |
| WO2009008913A2 (en) * | 2007-03-23 | 2009-01-15 | Schering Corporation | P1-nonepimerizable ketoamide inhibitors of hcv ns3 protease |
| US20090123423A1 (en) * | 2007-04-26 | 2009-05-14 | Yonghua Gai | Hydroxyamic analogs as hepatitis c virus serine protease inhibitor |
| US20090005387A1 (en) * | 2007-06-26 | 2009-01-01 | Deqiang Niu | Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors |
| WO2009014730A1 (en) * | 2007-07-26 | 2009-01-29 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
| US20090053175A1 (en) * | 2007-08-24 | 2009-02-26 | Yat Sun Or | Substitute pyrrolidine derivatives |
| US20090060874A1 (en) * | 2007-09-05 | 2009-03-05 | Yao-Ling Qiu | Bicyclic pyrrolidine derivatives |
| WO2009042668A2 (en) * | 2007-09-24 | 2009-04-02 | Achillion Pharmaceuticals, Inc. | Urea-containing peptides as inhibitors of viral replication |
| US20090082366A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched telaprevir |
| US20090111757A1 (en) * | 2007-10-25 | 2009-04-30 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
| US8383583B2 (en) * | 2007-10-26 | 2013-02-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors |
| US8426360B2 (en) * | 2007-11-13 | 2013-04-23 | Enanta Pharmaceuticals, Inc. | Carbocyclic oxime hepatitis C virus serine protease inhibitors |
| WO2009076166A2 (en) * | 2007-12-05 | 2009-06-18 | Enanta Pharmaceuticals, Inc. | Oximyl hcv serine protease inhibitors |
| KR20110005869A (ko) * | 2008-04-15 | 2011-01-19 | 인터뮨, 인크. | Ｃ형 간염 바이러스 복제의 신규한 마크로사이클릭 억제제 |
| EP2358736A1 (en) * | 2008-10-15 | 2011-08-24 | Intermune, Inc. | Therapeutic antiviral peptides |
| CA2790214A1 (en) | 2009-02-18 | 2010-08-26 | Wayne State University | Method for identifying a subpopulation of mammalian cells with distinctive ribosome translation profiles |
-
2008
- 2008-05-02 JP JP2010507576A patent/JP2010528987A/ja active Pending
- 2008-05-02 EP EP09177761A patent/EP2177523A1/en not_active Withdrawn
- 2008-05-02 WO PCT/US2008/062552 patent/WO2008137779A2/en not_active Ceased
- 2008-05-02 SG SG2011065919A patent/SG174809A1/en unknown
- 2008-05-02 US US12/114,639 patent/US20090155209A1/en not_active Abandoned
- 2008-05-02 EP EP08755035A patent/EP2160392A2/en not_active Withdrawn
- 2008-05-02 KR KR1020097024599A patent/KR20100024920A/ko not_active Withdrawn
- 2008-05-02 CA CA002686138A patent/CA2686138A1/en not_active Abandoned
- 2008-05-02 CL CL2008001274A patent/CL2008001274A1/es unknown
- 2008-05-02 CN CN200880018710A patent/CN101784549A/zh active Pending
- 2008-05-02 AU AU2008247509A patent/AU2008247509A1/en not_active Abandoned
- 2008-05-02 AP AP2009005053A patent/AP2009005053A0/en unknown
- 2008-05-02 NZ NZ581606A patent/NZ581606A/xx not_active IP Right Cessation
- 2008-05-02 MX MX2009011867A patent/MX2009011867A/es not_active Application Discontinuation
- 2008-05-02 BR BRPI0811020-4A patent/BRPI0811020A2/pt not_active IP Right Cessation
- 2008-05-02 EA EA200971026A patent/EA200971026A1/ru unknown
- 2008-05-05 AR ARP080101901A patent/AR066448A1/es unknown
- 2008-05-05 TW TW097116495A patent/TW200906830A/zh unknown
-
2009
- 2009-10-26 IL IL201757A patent/IL201757A0/en unknown
- 2009-10-30 TN TNP2009000457A patent/TN2009000457A1/fr unknown
- 2009-11-26 MA MA32378A patent/MA31496B1/fr unknown
- 2009-11-30 CO CO09136460A patent/CO6251243A2/es not_active Application Discontinuation
- 2009-12-02 EC EC2009009780A patent/ECSP099780A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010528987A5 (en:Method) | ||
| JP2010526834A5 (en:Method) | ||
| Mathé et al. | L-nucleoside enantiomers as antivirals drugs: a mini-review | |
| US6495677B1 (en) | Nucleoside compounds | |
| US6455508B1 (en) | Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides | |
| US6815542B2 (en) | Nucleoside compounds and uses thereof | |
| CN104470939B (zh) | 用于肝脏疾病的d型氨基酸化合物 | |
| US20040023921A1 (en) | Antiviral phosphonate compounds and methods therefor | |
| JP2018500372A5 (en:Method) | ||
| CA2488842A1 (en) | Carbocyclic nucleoside analogs as rna-antivirals | |
| NO326431B1 (no) | Nukleosidderivater som inhibitorer for RNA-avhengig RNA-viruspolymerase, farmasoytisk preparat og anvendelse av forbindelser for fremstilling av medkamenter | |
| RU2011139180A (ru) | Комбинация нуклеозидного ингибитора полимеразы и макроциклического ингибитора протеазы и ее применение для лечения гепатита с, фиброза печени и нарушенной печеночной функции | |
| AU2005267421A1 (en) | Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection | |
| JP2010515760A5 (en:Method) | ||
| HRP20130098T1 (hr) | MAKROCIKLIÄŚKE KARBOKSILNE KISELINE I ACILSULFONAMIDNI SPOJEVI KAO INHIBITORI REPLIKACIJE HCV-a | |
| RU2012117395A (ru) | Новые макроциклические ингибиторы репликации вируса гепатита с | |
| CA2488534A1 (en) | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | |
| JP2016503800A5 (en:Method) | ||
| RS56903B1 (sr) | Fuzioni proteini i kombinovane vakcine koje sadrže protein e i pilin a haemophilus influenzae | |
| AU2006280175A1 (en) | Ribonucleoside cyclic acetal derivatives for the treatment of RNA-dependent RNA viral infection | |
| JP2012519691A5 (en:Method) | ||
| Xie et al. | Nucleoside inhibitors of hepatitis C virus NS5B polymerase: a systematic review | |
| JP6857365B2 (ja) | 抗肝腫瘍ウイルス剤 | |
| Isobe et al. | Synthesis and structure–activity relationships of 2-substituted-8-hydroxyadenine derivatives as orally available interferon inducers without emetic side effects | |
| CN105348345A (zh) | 一种含有硫普罗宁结构的前药、其制备方法、药物组合物及其用途 |